Clinical Trials for Imugen

Explore 6 clinical trials worldwide

Showing 1-6 of 6 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Imugen

Clinical Trials (6)

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

PHASE1Recruiting

50 participants

Started: Oct 2, 2023 · Completed: May 31, 2029

1 condition1 sponsor8 locations

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

PHASE1Recruiting

100 participants

Started: May 17, 2022 · Completed: Nov 30, 2026

7 conditions1 sponsor12 locations

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

PHASE1Active, not recruiting

Started: Oct 18, 2021 · Completed: Mar 30, 2026

3 conditions3 sponsors1 location

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer

PHASE1Active, not recruiting

24 participants

Started: Nov 30, 2020 · Completed: May 31, 2025

6 conditions1 sponsor6 locations

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

75 participants

Started: Aug 25, 2020 · Completed: Dec 31, 2039

1 condition1 sponsor1 location

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

PHASE1Recruiting

129 participants

Started: Mar 11, 2019 · Completed: Jun 30, 2027

2 conditions1 sponsor22 locations